Abivax stock jumps as safety denominator eases obefazimod cancer worry

Abivax SA rose sharply in Paris on Tuesday after late Monday data gave investors a cleaner way to judge cancer risk in its ulcerative colitis drug programme. Euronext Paris was open for a regular session, with June 30 listed as a 0900-1730 CEST trading day.

EPA:ABVX · Health News · Pharmaceuticals · Stock Market
Abivax Shares Drop After Trial Win and Cancer Cases Raise Concerns

Abivax Shares Drop After Trial Win and Cancer Cases Raise Concerns

Abivax shares dropped hard Tuesday, despite positive late-stage trial results for its obefazimod drug. Investors focused on reported cancer and dysplasia cases in patients on the higher dose. The stock traded at 63.10 euros on Euronext Paris, well below Monday’s closing price of 111.80 euros, after touching 62.80 euros earlier. Over in the U.S., its Nasdaq ADRs were last at $72.86, down some 44% late in the session.
2 June 2026
····
Co-Diagnostics Stock Surges on Ebola Assay News — The Fine Print Is Big

Co-Diagnostics Stock Surges on Ebola Assay News — The Fine Print Is Big

Co-Diagnostics Inc. shares jumped in heavy U.S. trading on Tuesday after the molecular diagnostics company said it had completed a strategy for a possible Ebola assay tied to the Bundibugyo virus outbreak in the Democratic Republic of Congo and Uganda. The stock was recently up 51% at $2.07, after touching $2.73, on volume above 94 million shares; the iShares Russell 2000 exchange-traded fund, a small-cap stock basket, was down about 1.2%.
19 May 2026
···
Traws Pharma Stock Jumps As Biotech Targets Hantavirus After Cruise Ship Deaths

Traws Pharma Stock Jumps As Biotech Targets Hantavirus After Cruise Ship Deaths

Traws Pharma Inc. on Friday announced plans to push ahead with possible clinical candidates targeting hantavirus infections, shifting the antiviral developer’s focus after a lethal outbreak on a cruise ship. The company hasn’t disclosed a frontrunner. Chief Scientific Officer C. David Pauza said Traws “plans to rapidly advance clinical candidates.” Chief Medical Officer Robert R. Redfield described the move as an emergency push for “life-saving treatments.”
8 May 2026
···
Eli Lilly Stock Wobbles After Retatrutide Trial Win as Pricing Fears Bite

Eli Lilly Stock Wobbles After Retatrutide Trial Win as Pricing Fears Bite

Eli Lilly shares grabbed attention Thursday, with the drugmaker reporting its experimental obesity and diabetes therapy, retatrutide, hit the primary endpoint in a late-stage trial—showing notable drops in both weight and blood sugar. The stock last changed hands at $918.05, off 1.3% early, after Tuesday’s nearly 6% tumble that followed a rare downgrade from HSBC.
19 March 2026
···
1 2 3 4
Follow on Google News
Add as preferred source Open in Google News